The United Nations recently asked a group of experts across the world to recommend ways to persuade people to take a COVID-19 vaccine. Here is a summary of their suggestions.
Articles on Pfizer-BioNTech vaccine
Displaying 141 - 148 of 148 articles
COVID-19 vaccines are at risk of being undermined by vaccine hesitancy. Pharma must take steps to ensure transparency in data monitoring committees and trial data to build public trust in vaccines.
Because Pfizer-BioNTech and Moderna vaccines have been developed in record time, many wonder whether companies cut corners or compromised safety.
Early data shows that vaccines work for older people who are more at risk of severe COVID-19.
Two pharma companies have announced early COVID-19 vaccine trial results with over 90 per cent effectiveness. What does that mean for getting back to normal?
The funding, procurement, storage and distribution of a vaccine present huge challenges to all governments, including New Zealand’s.
Promising vaccines such as Pfizer’s will play a role in ending the pandemic – but widespread immunity isn’t yet on the horizon.
In science, vaccine efficacy and effectiveness mean something different.
Top contributors
-
Professor of Medicine, University of Virginia
-
Associate Professor of Pediatrics, University of Virginia
-
Associate Professor and ARC Future Fellow, The University of Western Australia
-
Professor, The Children's Hospital at Westmead Clinical School and Sydney Infectious Diseases Institute, University of Sydney
-
Professor of Pathology, Microbiology and Immunology, University of South Carolina
-
Professor of Pathology, Microbiology and Immunology, University of South Carolina
-
Vice-Chancellor's Research Fellow, School of Health and Biomedical Sciences, RMIT University
-
Pediatric Infectious Diseases Fellow, University of Pittsburgh
-
Research associate, Warren Alpert Medical School, Brown University, Brown University
-
Professor, School of Biomedical Sciences and Pharmacy, University of Newcastle
-
Instructor of Human Immunology, Emory University
-
Chair in Epidemiology, Deakin University
-
Associate Professor in Viral Immunology, University of Birmingham
-
Deputy Director of the HUMLOG (Humanitarian Logistics and Supply Chain Management Research) Institute, Hanken School of Economics
-
Professor of Health Service Operations, School of Pharmacy & Medical Sciences, University of Bradford